πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

8,395 results for β€œLa” Clear

  1. VX-985 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  2. Vagal Nerve Stimulation

    Rhythm Pharmaceuticals Netherlands B.V.

    Inflammation

    phase 1 other completed

    1 trial

  3. Vagus Nerve Stimulation

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Refractory Epilepsy

    phase 1 other active

    1 trial

  4. Valacyclovir

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  5. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  6. Vancomycin Pre-Treatment

    Seres Therapeutics

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 1 small molecule completed

    1 trial

  7. Varenicline, then placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Addiction

    phase 1 small molecule completed

    1 trial

  8. Velusetrag

    Theravance Biopharma Ireland Umited

    Alzheimer's Disease

    phase 1 small molecule completed

    1 trial

  9. Venetoclax

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  10. Venetoclax

    Karyopharm Therapeutics Inc

    Diffuse Large B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

  11. Venetoclax

    Karyopharm Therapeutics Inc

    Acute Leukemia of Ambiguous Lineage in Relapse

    phase 1 small molecule active

    1 trial

  12. Venezuelan Equine Encephalitis DNA Vaccine

    United Therapeutics Europe Ltd

    Vaccine Reaction

    phase 1 small molecule active

    1 trial

  13. Venlafaxine 25 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  14. Venlafaxine Hydrochloride

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    3 trials

  15. Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Istituto Gentili S.r.l.

    Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.

    phase 1 other active

    1 trial

  16. Volanesorsen

    IONIS PHARMACEUTICALS INC

    Abnormalities, Cardiovascular

    phase 1 small molecule completed

    1 trial

  17. Volasertib, low dose, d1q3w

    Boehringer Ingelheim

    Neoplasms

    phase 1 small molecule completed

    1 trial

  18. Vyxeos

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  19. Vyxeos 44 MG / 100 MG Liposome Injection

    Jazz Pharmaceuticals Ireland Limited

    Relapsed Pediatric AML

    phase 1 small molecule active

    1 trial

  20. WGc-0201 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 1 mab active

    1 trial

  21. X4P-001

    X4 Pharmaceuticals, Inc

    Melanoma

    phase 1 small molecule completed

    1 trial

  22. Y150

    Wuhan YZY Biopharma Co.,

    Relapsed or Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  23. YF476

    Blackmores Limited

    Hypergastrinaemia

    phase 1 small molecule completed

    2 trials

  24. YMN-A02 100ΞΌg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources